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Abstract. The objective of this review is to describe the current status of several intravaginal anti-HIV
microbicidal delivery systems these delivery systems and microbicidal compounds in the context of their
stage within clinical trials and their potential cervicovaginal defence successes. The global Human
Immuno-Deficiency Virus (HIV) pandemic continues to spread at a rate of more than 15,000 new
infections daily and sexually transmitted infections (STIs) can predispose people to acquiring HIV
infection. Male-to-female transmission is eight times more likely to occur than female-to-male
transmission due to the anatomical structure of the vagina as well as socio-economic factors and the
disempowerment of women that renders them unable to refuse unsafe sexual practices in some
communities. The increased incidence of HIV in women has identified the urgent need for efficacious
and safe intravaginal delivery of anti-HIVagents that can be used and controlled by women. To meet this
challenge, several intravaginal anti-HIV microbicidal delivery systems are in the process of been
developed. The outcomes of three main categories are discussed in this review: namely, dual-function
polymeric systems, non-polymeric systems and nanotechnology-based systems. These delivery systems
include formulations that modify the genital environment (e.g. polyacrylic acid gels and lactobacillus
gels), surfactants (e.g. sodium lauryl sulfate), polyanionic therapeutic polymers (e.g. carageenan and
carbomer/lactic acid gels), proteins (e.g. cyanovirin-N, monoclonal antibodies and thromspondin-1
peptides), protease inhibitors and other molecules (e.g. dendrimer based-gels and the molecular
condom). Intravaginal microbicide delivery systems are providing a new option for preventing the
transmission of STIs and HIV.
KEY WORDS: HIV/STIs; intravaginal drug delivery systems; microbicides; nanostructures; polymers;
prophylaxis.
INTRODUCTION
Infection with HIV remains an incurable condition (1,2).
The highest rate of HIV transmission is through the exposure
of the vaginal mucosal surface to HIV during sexual
intercourse. Until January 2006, the Joint United Nations
Programme on HIV/AIDS (UNAIDS) and the World Health
Organization (WHO) estimated that AIDS had caused the
mortality of more than 25 million people since it was first
recognized, making it one of the most destructive epidemics
in recorded history (3,4). The majority of deaths have
occurred in sub-Saharan Africa where the prevalence rate for
sexually active adults is greater than 35 (5–7). This culminates
in causing the death of economically active adults with
the accompanied macro-economic challenges. At present,
the current use of antiretroviral treatment reduces both the
mortality and morbidity associated with HIV infection, but
routine access to antiretroviral medication is not available in
all countries. Sexually transmitted infections (STIs) also
predispose people to acquiring HIV/AIDS through the
interference of the integrity of the vaginal epithelium. The
presence of untreated STIs enhances both the acquisition and
transmission of HIV by a factor of up to 10. Thus, effective
STI treatment is an important HIV prevention strategy (8–11).
Several therapeutic agents for curing HIV/AIDS have
been developed, but, to date none has been proven to be
successful. A Reproductive Health Research Unit study by
Pettifor et al. (12) showed an extremely high percentage of
respondents (93%), identified condom use as being an
effective preventative measure but 67% did not use condoms
consistently and 31% had never used condoms. In the wake
of this other effective female controlled measures that can
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The most compelling solution to HIV/AIDS is an effective
vaccine. However, after 25 years of research, development of
an effective vaccine has remained unsuccessful due to various
obstacles including inadequate resources, regulatory capacity
concerns, intellectual property issues and mainly the scientific
challenges (8,13,14). Therefore, it is likely that the greatest
potential for prevention of STIs and HIV/AIDS will lie in the
development of effective intravaginal microbicidal delivery
systems (Table I).
Studies have shown that the vagina is a suitable site for
local and systemic delivery of drugs (14–16). Traditionally, the
intravaginal route has been used for the delivery of locally
acting drugs such as antibacterials, antifungals, antiproto-
zoals, antivirals, labor-inducing and spermicidal agents, pros-
taglandins and steroids. The large surface area, permeability
and rich blood supply of the mucous membrane of the vagina,
provide significant potential for the delivery of a wide range
of compounds, including peptides and proteins, and offers an
alternative to the parenteral route of administration for
numerous bioactive substances. However, despite all these
advantages, the intravaginal route has not been extensively
explored as a mode for drug delivery due to menstrual cycle
variations (14). Intravaginal drug delivery systems have
traditionally been used to deliver contraceptives and drugs
to treat vaginal infections. Formulations have included
pessaries and tablets designed after the advent of rectal
suppositories. The first intravaginal controlled drug delivery
system was developed in 1970, using a vaginal ring for the
delivery of medroxyprogesterone acetate for contraception
(14). However, tablets, creams, and suppositories are now the
most conventional formulations in vaginal drug delivery while
vaginal rings are more commonly employed for long-term
drug delivery.
Recent advances have been made in the area of
bioadhesive gels, microparticles and tablets, which show great
promise for use as controlled intravaginal microbicide deliv-
ery systems (17–19). Numerous hydrophilic polymers and
hydrogels have been used in a number of vaginal products
(20–22,23,24) that violate the HIV life-cycle at multiple
steps, have increased efficacy, limited cross-resistance and
minimize microbicide-induced host toxicity (25,26). The
objective of this review is therefore to describe the recent
developments in intravaginal delivery systems for micro-
bicides employed for the prophylaxis of HIV/AIDS and
prevention of STIs.
METHODS
Given the devastating effects of the HIV/AIDS epidemic
and the continuing difficulties in developing an effective HIV
vaccine, there is a clear scientific rationale for developing
alternative methods to prevent STIs and the transmission of
HIV infection. Microbicides circumvent many of the immu-
nological difficulties associated with HIV vaccine develop-
ment and make topical formulations a more realistic goal,
especially in the short term (27,28). The most promising
strategy currently being pursued is the utilization of intra-
vaginal delivery systems for microbicides (13,26,29–34).
Microbicides are chemical substances that when inserted
intravaginally prior to sexual intercourse, have the potential
to either prevent or reduce the risk of STIs and HIV
transmission once released from a delivery system (24,30,31).
The potential for developing controlled release formulations
for long-term intravaginal delivery of microbicides has recently
gained momentum and may overcome challenges relating to
compliance, acceptability and efficacy associated with current
gel-based formulations (30,35). Furthermore, the emergence
of resistant HIV strains and toxic side-effects of current
antiretroviral drugs (ARVs) require intravaginal delivery
systems with superior safety profiles and potential for
improved patient compliance.
An intravaginal microbicidal delivery system combining
several mechanisms of preventing the transmission of STIs
and HIV would need to possess added effectiveness and less
side-effects than a delivery system having a single mechanism
(26) (Fig. 1). The challenge is to design a delivery system that
is able to provide high concentrations of the microbicidal
compound in the vagina over a prolonged period of time (36).
Studies have indicated that dosages in first-generation micro-
bicides remain effective only for a few hours and therefore
necessitate administration shortly before coitus (37). For
controlled, zero-order release sustained over prolonged
periods (days extending to months), solid polymeric systems
may be the most suitable biocompatible delivery system with
the physicochemical nature of the microbicide or drug to be
delivered.
Current Intravaginal Microbicide Delivery Methods
for Preventing the Transmission of STIs and HIV
The majority of microbicidal delivery systems for intra-
vaginal administration that have been developed and evalu-
ated in ongoing clinical trials are conventional semi-solid
aqueous gels and vaginal ring formulations. These are
designed to provide a single dose of a microbicidal agent
(38–42). Intravaginal delivery systems for microbicides have
been formulated and traditionally include a large variety of
pharmaceutical dosage forms such as semi-solids, tablets,
capsules, pessaries, liquid preparations, vaginal films, vaginal
rings, foams, and tampons. Currently, the maximum duration
of drug release for intravaginal microbicidal delivery systems
is as follows: (1) Vaginal gels (6 h) (42,43), (2) vaginal tablets
(8 h) (44,45), and (3) vaginal rings (71 days) (8,46,69). Vaginal
gels and tablets have rapid release rates which, for effective
use, ultimately require administration several times a day.
Vaginal rings have adequate release rates but have only been
formulated for preventing the transmission of HIV and as a
Table I. Desirable Criteria for Ideal Intravaginal Microbicidal
Delivery Systems
Criteria
Simple to manufacture, cost effective and easy to apply thus
facilitating patient compliance
Non-irritative and free from producing any physical discomfort
Provide immediate and sustained protection by releasing the
microbicide in a controlled manner over a prolonged period of time
Have suitable vaginal retention and distribution
Be versatile against various pathogens encompassing STIs and HIV
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for vaginal drug delivery include creams, ointments, and gels
(14,26,37).
Over the past decade, there have been major advances in
the field of microbicidal delivery with diverse types of
delivery systems in various stages of development (47). The
ultimate success of an intravaginal microbicide delivery
system requires consideration of variables including the
microbicidal agent, vaginal physiology and the design of the
delivery system. Furthermore, bioavailability is affected by
numerous physiological factors, and the ability of the
formulation to effectively deliver the microbicide may vary
with the menstrual cycle, pH variations and the presence of
co-pathogens (48,49).
Targeting HIV entry into the body is a favored preven-
tative approach as it is the initial step in the process of
infection. Several readily available anionic polymers interfere
with the entry processes of HIV, and hence these polymers
qualify as primary candidates for designing various micro-
bicidal delivery formulations (36). However, few of these
formulations have been tested in Phase I/II clinical trials, in
HIV-uninfected, and HIV-infected populations (50). Current
multi-center Phase I/II safety and Phase II/III efficacy studies
are being conducted or planned in different geographical
locations, by various groups which aim to design systems for
rapid clinical applications.
Design of Intravaginal Microbicide Delivery Systems
Intravaginal delivery may be designed for administration
of microbicides by using an applicator or specifically designed
systems for intravaginal administration. In general, based on
the delivery system or the microbicide used, drug absorption,
distribution and residence time in the vagina may vary. Early
studies by Johnson and Masters (51) showed that the micro-
bicide distribution in the vaginal tissue varies considerably
with the nature of the delivery system. Solutions, suspensions
and foams displayed greater superiority over tablet dosage
forms. Ideally, a vaginal delivery system that is intended for
localized microbicidal delivery should distribute uniformly
throughout the vaginal cavity. Thus, for a local effect to occur
in the vagina, semi-solid, or fast dissolving solid systems are
required. Bioadhesive delivery systems or intravaginal ring
systems are more suited for topical effects. Currently there is
no data available regarding the bioavailability of most intra-
vaginal microbicide delivery systems after extended vaginal
exposure (50,52). Engineering and materials science may
provide critical and new information to the process of
designing and developing superior intravaginal microbicide
delivery systems. First-generation microbicidal compounds
that are currently under investigation are expected to be
available within a few years. These systems may only be 50–
60% effective in delivering microbicides, but even with this
efficacy if used (37) by only 20% of women, in 73 low-income
countries, it may still lead to the prevention of 2.5 million new
infections during a 3-year period (26,37).
Creams and Gels
To date the greatest number of intravaginal drug delivery
systems for microbicides, by far, is in the form of creams or
gels. Although commonly used for the topical intravaginal
delivery of microbicides, these systems are messy, uncomfort-
able and may not provide an exact dose due to non-uniform
distribution and leakage (53). To evaluate the efficacy of a
3-day course of clindamycin vaginal cream in the treatment of
bacterial vaginosis, Lamont et al.( 54) performed a random-
ized, placebo controlled trial in pregnant women and found
Fig. 1. Schematic depicting the various mechanisms of preventing the transmission of sexually transmitted infections and HIV by employing
microbicide delivery systems (adapted: Stone et al.( 38))
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efficacious than placebo. During the past few years, consid-
erable work has been done on the development of hydrogel
controlled release microbicide delivery systems (14–19,55,95).
For example, a 3% alginate gel of nonoxynol-9 has been
investigated for intravaginal spermicidal activity (55). The
study found that the spermicidal activity and the diffusion of
the agent changed with the pH and osmolarity of the
formulation. Recently, a gel microemulsion-based spermicide
formulation, phenyl phosphate derivative of zidovudine, with
anti-HIV effect, has been developed (56). Multiple intra-
vaginal applications of this drug as a microemulsion gel
formulation did not cause any damage in the vaginal
epithelium in the rabbit model (57–59).
Tablets and Suppositories
A large number of intravaginal delivery systems are also
available in the form of tablets or suppositories. Some authors
use the terms pessaries and suppositories interchangeably and
consider vaginal tablets as a separate dosage form. These
formulations are designed to melt in the vaginal cavity and
release the microbicide over several hours. Suppositories are
most commonly used to administer drugs for cervical ripening
prior to child birth and for local delivery of various drugs.
Vaginal tablets may contain binders, disintegrants and other
excipients that are used to prepare conventional oral tablets.
Mucoadhesive polymers are sometimes used in tablet for-
mulations to increase the vaginal residence time of the
microbicide been delivered. Other vaginal tablet-like formu-
lations are extrapolations of silicone-based vaginal rings.
Research groups have studied the release of microbicides
from silicone matrices (60,61). Release studies were per-
formed in vitro for up to 1 year and in vivo in rabbits for up
to 52 days. Both in vitro and in vivo studies showed
consistent release profiles over time, showing that micro-
bicide delivery is controlled by diffusion from the silicone
delivery device and was not limited by absorption through
the vaginal epithelium.
Vaginal Rings
Vaginal rings are circular ring-type drug delivery devices
designed to release microbicides in a controlled manner after
insertion (8,31,62). The advantages of such a device are that it
can be controlled by the user; does not interfere with coitus
and allows for the continuous delivery of microbicidal
compounds. In simple vaginal rings, the microbicide is
homogeneously dispersed within a polymeric ring with the
surface of the ring releasing the microbicide faster than the
inner layers. The key challenge in development of these
systems is finding the optimum dose that will deliver the least
amount of microbicide necessary to ensure protection.
Advances have been made on the original two-layer ring
system by adding a third, outer, rate controlling drug-free
elastomer layer to minimize the drug concentration spike
(63). Much of the methods in vaginal ring literature relates to
the commonly used polymer, poly(dimethylsiloxane) or
silicone devices, although other elastomeric polymers such
as ethylene vinyl acetate and styrene butandiene block
copolymers have been tested in recent years (46,64). Most
women judged the ring easy to insert and remove, and no
side-effects are experienced (65–68).
Bioadhesive Intravaginal Systems
Most conventional intravaginal formulations however
are associated with disadvantages of low retention to the
vaginal epithelium, leakage and messiness, thereby causing
poor patient compliance. To circumvent these challenges,
bioadhesive microbicidal delivery systems are being propa-
gated (67). Bioadhesive polymers that have been used for
intravaginal formulations include polycarbophil, hydroxypro-
pylcellulose and polyacrylic acid (70). The first bioadhesive
systems for vaginal drug delivery were in the form of tablets
for the delivery of bleomycin, an anti-caner agent (70–75).
Attempts have also been made to delivery of microbicides
using bioadhesive microparticulate vaginal systems (73–78,99).
These systems may be a multi-phase liquid or a semi-solid, but
have been designed so as not to seep from the vagina like
pessary formulations. Table II lists the numerous intravaginal
delivery systems that have been identified.
RESULTS AND DISCUSSION
Dual-Function Polymers Employed in the Design
of Intravaginal Microbicide Delivery Systems: As Excipients
with Potential Therapeutic Activity
A Carageenan Vaginal Gel Formulation for HIV and Human
Papilloma Virus Inhibition
Carraguard™ is a gel-like delivery system comprising
carageenan that acts as an absorption inhibitor by coating the
vagina. Carageenan is an excipient that is used as a gelling
agent and presents as one of the most promising class of
potential microbicidal compounds (77–82,86)( T a b l eIII).
Carraguard™ has several advantages over other vaginal
microbicide delivery systems such as a higher bioavailability,
safety, versatility, and economic saving (83). There appears to
be no effect on sperm motility (84–86).
Table II. Classification of the Numerous Intravaginal Compounds Delivered Intravaginally
Classification Compounds
Polymeric Carageenan, Monocaprin, Polyacrylic Acid, Lactobacillus, Cellulose Acetate Phthalate, Cellulose Sulfate, Polystyrene
Sulfonate, Naphthalene Sulfonate, Sulfated Polyvinyl Alcohol and Lactic Acid
Non-Polymeric Cetyl Betaine, Myristamine Oxide, Stampidine, Cyanovirin-N, Monoclonal Antibodies, Lyposomes, Thrombospondin-1,
Lime Juice, Yoghurt, Tenofovir and Zidovudine
Nano-Structured Dendrimers, Thiourea, Silver, Polystyrene and Sodium Lauryl Sulfate
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Reverse Transcriptase Inhibitor
PC-815 gel is an intravaginal delivery system combining a
microbicide containing carageenan with MIV-150. MIV-150 is
an NNRTI which prevents HIV-infected cells from replicating
(85,87). Pre-clinical tests of MIV-150 have shown a significant
increase of activity against HIV-1 primary isolates with no
toxic effects. However, it has a low oral bioavailability which
makes it an ideal compound for intravaginal delivery, since
the chances of causing systemic side-effects become dimin-
ished (85). In vitro pharmacological studies have indicated
that the PC-815 delivery system has significantly higher
activity against HIV than that of the Carraguard™ system
(85).
A Topical Non-Contraceptive Carageenan Gel Formulation
PC-515 gel is a topical gel formulation containing 3% w/
w carageenan. It is under development as a non-contraceptive
microbicidal delivery system that may offer HIV protection
while allowing women to conceive. Zacharopoulos and
Phillips (88) showed that PC-515 protected against HSV with
an effect superior to many microbicidal delivery systems. The
protective effect was seen across a wide range of pH levels
and lasted up to 18 h (88). PC-515 has undergone develop-
mental trials in humans to ascertain the overall performance
of the formulation (89).
A Polyacrylic Acid-Based Gel Formulation
A polyacrylic acid polymeric gel (BufferGel™, RePro-
tect, LLC, Baltimore, MD, USA), that is currently under
Phase II clinical trials for contraception and the prevention of
HIV (8). Its maintains the natural acidity of the vagina to
ensure survival of lactobacilli that are able to produce lactic
acid and hydrogen peroxide which inactivate many pathogens
that cause STIs (82,90). BufferGel™ acidifies semen, thereby
destroying sperm cells, HIV and a wide range of STI
pathogens during sexual intercourse and thus creates a
physical barrier that inhibits the passage of pathogens into
the vaginal and cervical epithelium (90–93) (Fig. 2). A similar
Table III. Chemical Structures of Polymeric Microbicide Compounds
Compound Structure Reference
Kappa Carageenan  Absorption Inhibitor [80] 
Carbomer  Interruption of HIV cell binding
Cellulose Acetate  Inactivates HIV and HSV
Phthalate
Capric Acid  Inactivates HIV and HSV
Polystyrene Sulfonate Activity against HIV and HSV
H3C
OH
O
[109]
[115]
[118]
[74]
Key Function
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formulation which is currently under Phase III clinical trials
(94).
A Lactobacillus Crispatus Soft-Gel Capsule Formulation
A Lactobacillus crispatus (LC) microbicidal agent (Lactin
Vaginal Capsules™, Gynelogix, Louisville, CO, USA) which
acts by re-colonizing the vagina with lactobacillus once
released from the soft-gel capsule has been developed (47).
LC assists in keeping the vagina free from infection by
producing hydrogen-peroxide. Normally, upon disturbing the
ecology of the vagina either through infection, douching, or
poor hygiene when the vaginal pH rises above 4.5, a loss of
lactobacilli occurs, resulting in the overgrowth of other bacteria
and bacterial vaginosis which is a significant risk for pre-term
labor, amnionitis, PID and HIV acquisition (82,90).
Thermosensitive Gel Formulations
Thermosensitive gels are systems that alter the physical
characteristics of the gel with exposure to environmental
changes within the vagina usually in the range of 25–37°C
(96–98). Commonly used thermosensitive polymers for intra-
vaginal microbicide delivery include the polysaccharides,
polyacrylamides, poloxamers, polyoxides, polyesters, and a
few liposome-based systems. Poloxamer hydrogels represent
the most extensively studied thermosensitive polymeric
systems, while polysaccharides usually demonstrate good
biocompatibility and/or biodegradability (96). Gels, which
present mucoadhesive behaviour, are prepared with mixtures
of poloxamers and polycarbophil (96,98,100).
Long-Chain Sulfated Polysaccharides and Sulfonated
Polymeric Formulations
A poly(sodium 4-styrene sulfonate) (T-PSS) and cellu-
lose sulfate (Ushercell™, Polydex Pharmaceuticals, Toronto,
Canada) microbicidal delivery systems have reached Phase I
and III clinical trials respectively (Table III). Both are known
to inhibit multiplication or activity of HIV, and various other
pathogens (101–106). Gel formulations tested contained 5–
10% w/w T-PSS, hydroxyethylcellulose and propylene glycol
(107). T-PSS has been proven safe in animal studies (103,
106). As a result, the US FDA approved an Investigational
New Drug (IND) application for both products. However, the
Contraceptive Research and Development Program reported
that interim data, from a trial where women received Usher-
cell™, the prevalence of HIV infection was greater in these
women, receiving the delivery system then those receiving the
placebo gel (108–111). Thus, these clinical trials have been
halted pending the outcome of these investigations.
A Carbomer, Lactic Acid and Naphthalene Sulfonate
Gel Formulation
A gel comprising a synthetic carbomer, a lactate buffer
system (Table III) and naphthalene sulfonate as an antiviral
agent (PRO 2000™ Gel, Indevus Pharmaceuticals, Inc.
Lexington, MA, USA) is currently under development for
the prevention of STIs and HIV (112,113). PRO 2000™ Gel
disrupts any interaction of the virus with target cells. Results
from in vivo animal studies have shown that PRO 2000™ gel
is safe and well tolerated (114–116). Currently it is under
Phase III clinical trials where it has displayed promising
Fig. 2. Smears of vaginal microflora cells. a and b L. crispatus; c and d non-L. crispatus; e and f L. crispatus and non-L. crispatus; g and h,
Gram+ve rods; i and j Lactobacillus and vaginosis bacteria; k and l bacterial vaginosis (Verhelst et al.( 91))
510 Ndesendo et al.results (117). PRO 2000™ gels are also compatible with the
use of condoms and may even provide more benefits for
women worldwide (25).
A Micronized Cellulose Acetate Phthalate Gel Formulation
Cellulose Acetate Phthalate (CAP) has been used for
several decades in the pharmaceutical industry for enteric
coating of oral tablets and capsules (Table III). Micronized
CAP has shown to adsorb and inactivate HIV-1, HSV and
other STIs (118). Earlier studies indicate that a gel formulation
of micronized CAP has the potential to be used for topical
intravaginal delivery of microbicides for prevention of STIs
and HIV (119). It is converted into a gel and therefore does
not have to be removed following its application (119). CAP is
one of the potential anti-HIV vaginal gel formulations that are
under Phase II clinical trials (120).
A Monocaprin-Loaded Hydrogel Formulation
Monocaprin hydrogel formulations possess potent micro-
bicidal activity against HIV, HSV, Chlamydia trachomatis and
Neisseria gonorrhea (121,122) (Table III). In vitro studies have
shown that monocaprin gels formulated using sodium car-
boxymethylcellulose and polyvinylpyrrolidone or carbomer
and hydroxypropylmethylcellulose, are virucidal to HSV-1 and
less cytotoxic than nonoxynol-9 (123). In vivo studies in mice
showed that the gels were non-irritant and non-toxic in the
vagina (122). The formulation could be further pursued as
intravaginal microbicide delivery systems for the prevention
of STIs and HIV.
Polystyrene Sulfonate Vaginal Tablets
Polystyrene Sulfonate (PSS) is also a microbicide that
has been developed as an intravaginal tablet formulation (77)
(Table III). When PSS intravaginal tablets were used as a
microbicide delivery system it was shown that PSS provided
superior antimicrobial activity against HIV and HSV (77).
This formulation did not immobilize sperm, was not cytotoxic
and did not inhibit normal vaginal microflora. This demon-
strates its potential as a safe and effective vaginal microbicide
delivery system for the prevention STIs and HIV (77,124).
Non-Polymeric Intravaginal Microbicide Delivery Systems
for Preventing the Transmission of STIs and HIV
A Cetyl Betaine and Myristamine Oxide Combinatory
Cream Formulation
C31G cream (Savvy™, Cellegy Pharmaceuticals, Inc,
San Francisco, CA, USA) comprises a broad-spectrum
antimicrobial and spermicidal agent namely cetyl betaine
and myristamine oxide that displays activity against bacteria,
fungi, yeasts, and enveloped viruses (125) (Table IV). These
effects occur once the microbicidal agent diffuses through the
cream, which is formulated with hydroxyethylcellulose that
also acts as a surface-active microbicide. In Phase III clinical
trials, the delivery system has shown the ability to prevent
HIV-1 and HIV-2 transmission and also has a desirable
contraceptive activity (49,50).
A Non-Nucleoside Reverse Transcriptase Inhibitor-Loaded
Gel Formulation
UC781 is a NNRTI that is incorporated into gel
formulations (Table IV). Short pre-treatment both of isolated
cells and human cervical tissue explants, with low concen-
trations of UC781 provided a strong barrier to subsequent
virus infection by cell-free or cell-associated HIV-1 (126,127).
UC781 is readily formulated as an appropriate carrier for
vaginal application in the form of Replens® Gel (Anglian
Pharma, Hertfordshire, UK). It also has a favorable toxicity
profile (126). UC781 warrants further clinical assessment for
its use as a topical intravaginal delivery system.
A Nucleotide Analogue-Loaded Gel Formulation
PMPA Gel (Tenofovir™, Gilead Sciences, Foster City,
CA, USA) is a microbicide delivery system that blocks HIV
replication (128). Tenofovir™ could be absorbed by the
vaginal epithelium to prohibit the replication and penetration
of the virus in the outer cells of the vaginal wall (Table IV).
Preliminary results from studies of Tenofovir™ are encour-
aging and indicate that it may be a new microbicide delivery
system to consider as part of a potent anti-HIV regimen.
Tenofovir™ may require less frequent dosing than currently
available therapies and appears to be active against resistant
strains of HIV (83).
A Novel Synthetically Derived Aryl Phosphate-Loaded Gel
Formulation
Stampidine is a derivative of stavudine (Table IV)t h a t
is a potent, broad-spectrum anti-HIV agent with potential to
be used as a newer class of non-spermicidal microbicides
(129). A vaginal gel formulation of stampidine was tested
for its potential to cause vaginal mucosal toxicity in New
Zealand white rabbits (129,130). Application of 0.5–2.0%
w/w of a stampidine formulation, produced minimal-to-mild
vaginal irritation, which is in an acceptable range for a
clinical trial (130). Thus, the favorable toxicity profile of
intravaginally administered stampidine-containing gel may
provide the foundation for its clinical development as a safe
and effective broad-spectrum anti-HIV microbicide delivery
system.
A Cyanovirin-N Gel Formulation for Chemotherapeutic
and Immunoprophylactic Prevention of HIV
Cyanovirin-N (CV-N) is a novel protein that has generated
interest for the chemotherapy of HIV infection (131,132). A
possible combined chemotherapeutic and immunoprophylactic
approach for preventing HIV may be based upon the concept
that continuous exposure of HIV to gp120-binding agents from
a gel formulation may diminish glycosylation sites, thus
triggering the production of specific neutralizing antibodies to
previously hidden gp120 epitopes (133–136). CV-N inhibits the
fusion of HIV-infected cells as well as cell-to-cell transmission
of HIV-1 infection. CV-N is a promising candidate as a
microbicide gel formulation for intravaginal delivery (137). In
cell cultures it is non-toxic and resistant to degradation with a
shelf-life of at least 6 months (131).
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Gel-Like Formulation
Sodium lauryl sulfate (SLS) is currently under Phase II
clinical trials as an entry fusion inhibitor (9)( I n v i s i b l e
Condom™, Laval University, Infectious Diseases Research
Center, Quebec City, QC, Canada). Ward and Ashley (138)
were demonstrated that SLS at low concentrations is a potent
inactivator of rotavirus and poliovirus. Previous in vitro
studies have demonstrated the ability of SLS to inhibit the
infective capacity of different enveloped viruses such as HSV-
1, HSV-2, and HIV-1 (139–141). This suggested that SLS
could be a candidate for use as an intravaginal microbicide
gel formulation to prevent the sexual transmission of STIs
and HIV (139).
Dapivirine Anti-HIV Vaginal Rings
While most research on microbicides has focused on
single-dose and semi-solid topical gels, ring-based delivery
systems could reduce the burden of patient compliance.
These can provide long-term, controlled release of micro-
bicides that may confer continuous protection against STIs
and heterosexually transmitted HIV, and rule out the need for
application of the intravaginal microbicidal delivery system
near the moment of sexual intercourse (63, 142). Dapivirine,
which is also known as TMC120, is a potent non-nucleoside
reverse transcriptase inhibitor that is the only vaginal ring
system used as an intravaginal microbicide delivery system
for preventing the transmission of STIs and HIV (9,142,143)
(Table IV).
Polyherbal Anti-HIV Praneem-Loaded Vaginal Tablets
Praneem has been developed as an anti-HIV vaginal
tablet formulation. Praneem contains purified extracts of
Azadirachta indica also known as the Neem tree. Praneem
has preventative activity against STIs in vitro and therefore it
has been developed as a possible intravaginal microbicide
delivery system. Phase I safety studies on Praneem tablets,
Table IV. Chemical Structures of Non-polymeric Microbicide Compounds
Compound Structure Key Function                             Reference
Cetyl Betaine Broad-spectrum antimicrobial
Myristamine     Spermicidal agent [122]
UC781             Tight binding NNRTI [123]
Tenofovir  Blocks HIV replication [125]
Stampidine      Broad-spectrum anti-HIV agent [126]
Dapirivine          Potent NNRTI [139]
  [122]
512 Ndesendo et al.revealed that the formulation is safe for once daily intra-
vaginal use, for 14 consecutive days, in sexually active
uninfected women (113).
Nanotechnology-Based Intravaginal Microbicide Delivery
Systems
A Dendrimer-Based Microbicide Formulation
SPL2008 (VivaGel™, Starpharma Ltd., Melbourne,
Victoria, Australia) is a dendrimer-based microbicide
delivery system in which the dendrimer is not a carrier
but an active ingredient (107,144). SPL7013 emerged as the
most promising dendrimer after pre-clinical studies, and has
been formulated as a gel that is undergoing clinical trials
(145). Bernstein et al. (146)s h o w e dt h a ta5 %w/w Carbopol
gel can be a suitable vehicle for the intravaginal adminis-
tration of SPL7013 (147). SPL7013 binds and blocks HIV-1
thereby preventing STIs, including HIV and genital herpes
(108,144,141). Phase I trials have shown that VivaGel™
is safe and well-tolerated. Further trials are being con-
ducted to test its efficacy against genital herpes and HIV
(108,144).
Silver Nanoparticles Employed as Microbicide Delivery
Systems
Various studies are currently investigating the production
of a novel class of nanomaterials called, protein-conjugated
noble metal nanoparticles (147–149). The production
involves direct conjugation of noble-metal nanoparticles with
proteins that may be used in numerous forms including
antiviral and antibacterial delivery systems (148,150). Under
certain pH conditions, disulfide bonds of the protein are
available for direct bonding with the noble metal nano-
particles. The polypeptide backbone of the protein remains
intact and the method does not affect the functional groups
of the constituent amino acid residues. Silver nanoparticles
take advantage of the microbicide properties of silver with
different materials to produce effective microbicide deliv-
ery systems for preventing STIs and HIV transmission
(147,148,151).
Polystyrene Nanospheres as Microbicide Delivery Systems
Mucosal secretory IgA may have an important role in
the prevention of HIV-1 transmission during sexual inter-
course. Therefore, substances that induce HIV-1-specific IgA
antibodies have shown promise for use as prophylactic
vaccines against HIV-1 infection. It has been reported that
Concanavalin A-immobilized Polystyrene Nanospheres (Con
A-NS) could efficiently capture HIV-1 particles on the surface
and that intravaginal immunization with the nanospheres
induces vaginal anti-HIV-1 IgA antibodies in mice (152).
Thus, application of Con A-NS by intravaginal delivery is a
practical approach to promote an effective immunization
approach. Likewise, lectin-immobilized polystyrene nano-
spheres have been synthesized and examined for HIV-1
capturing abilities (153,154).
A Gel-Like Molecular Condom Formulation as a Barrier
for STIs and HIV Transmission
The molecular condom is a recently developed anti-HIV
vaginal gel (38). The term “molecular condom” arises from
the concept that the polymer construct is liquid at room
temperature and, when applied intravaginally, spreads and
converts to a gel that effectively coats the vaginal wall (38).
The gel is designed to release the anti-HIV bioactives upon
contact with semen during sexual intercourse. It is a hydrogel
sensitive to body temperature and pH, and serves as a “smart
semen-triggered vaginal microbicide delivery vehicle.” The
system is nano-enabled and explores the use of bioresponsive
drug delivery by tailoring the physiological and mechanical
requirements essential for intravaginal application. The
ultimate hope for this technology is to protect women and
unborn or nursing children from HIV (38).
Other Microbicidal Compounds Currently
Under Investigation
Thiophen-Thiourea: A Non-Nucleoside Reverse
Transcriptase Inhibitor
PHI-443 is a rationally designed novel thiophen–thiourea
NNRTI with potent activity against HIV-1 isolates (94)
(Table V). Exposure of human sperm to PHI-443 at doses
30,000 times greater than those that yield effective concen-
trations against HIV has shown that PHI-443 has no effects
on sperm motility, kinematics, cervical mucus penetrability, or
the viability of vaginal and cervical epithelial cells. Repeated
intravaginal administration of 0.5–2% w/w of PHI-443 as a gel
has been found to be safe in rabbits (94). Thus, PHI-443 has
potential as a prophylactic broad-spectrum anti-HIV micro-
bicide without contraceptive activity.
A Secretory Leukocyte Protease Inhibitor
Secretory leukocyte protease inhibitor (SLPI) is an
endogenous antimicrobial agent found in mucosal tissue and
saliva, most prominently in mucosal sites open to the external
environment. Its original function is believed to be an anti-
protease defense against neutrophils at the mucosal surfaces
(155). In vitro laboratory studies have shown that SLPI can
inhibit HIVentry into CD4
+ cells by interacting with targeted
cells blocking access as a barrier function. This may provide a
reason as to the low rate of HIV infection through oral sex
due to the presence of SLPI in saliva. Data from studies
of various mucosal tissues such as the mouth, gut, rectum
and endocervix, suggest an inverse relationship between
infectious HIV and the presence of SLPI (155). Further
studies of SLPI as “a natural endogenous product” need to be
performed since it has been shown to have the potential to
function as an effective microbicide (155–157).
Monoclonal Antibodies as Microbicides
Monoclonal antibodies are molecules synthesized by the
immune system as ‘mirror images’ of foreign substances
(158). A long-range goal in vaginal protection is to develop
monoclonal human antibodies in a microbicidal gel for
513 A Review of Current Intravaginal Drug Delivery Approachesprotecting genital skin and epithelia against infections by
topical passive immunization. Mucus secretions contain large
quantities of antibodies that are highly specific and potent
agents for preventing the infectious entry of pathogens
(Table V). Monoclonal synthetic antibodies against sperm,
HIV, and other STI pathogens can be applied directly to
genital skin and epithelia for protection (159,160). This may
closely mimic the normal function of antibodies in the
mucosal immune system, e.g., antibodies in breast milk help
protect the surfaces of the mouth, nose, eyes, and digestive
tract of the baby. To date, the results of studies performed
indicate that monoclonal antibodies delivered to the vagina
may help prevent pregnancy as well as sexual transmission of
genital herpes and HIV (161–164).
Thrombospondin-1 as a Barrier to Mucosal Transmission
of HIV-1
During an investigation of the physiology of HIV
inhibition by human saliva, laboratory studies identified
thrombospondin-1 (TSP1) to have potential as a barrier
agent against local mucosal transmission of HIV-1 (165–169)
(Fig. 3). TSP1 is found in lower concentrations in plasma and
most body fluids (170,172), but not in saliva (165). Since TSP1
is a high molecular mass compound, difficult to purify, and
labile in the presence of tissue proteases, it is an impractical
candidate to be formulated as a localized intravaginal
delivery system. Characterization of alternative TSP1 peptide
modifications currently under design may identify conforma-
tions that are more potent and stable and thus better for
localized intravaginal therapy (166).
Short Interfering RNA as Potential Liposomal Microbicide
Delivery Systems
Short interfering RNA (siRNA) is a type of microbicide
based on RNA interference (RNAi), a natural selective
process for turning off genes, which holds great potential in
its ability to treat disease at the genetic level. RNAi is
triggered by siRNA molecules that engage a group of cellular
proteins, known as RNA-induced silencing complexes
(RISC). RISC guides the siRNA to its target messenger
Table V. Chemical Structures of Other Novel Microbicide Compounds
Compound Structure Key Function                               Reference
Thiophen-Thiourea NNRTI against drug-resistant HIV                  [91]
Monoclonal  Antibodies Passive immunization       [155]
Lime Juice       Retards HIV transmission                  [169]
Yoghurt                  Inhibits transmission of HIV                [170]
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514 Ndesendo et al.RNA (mRNA) by complementary base pairing and splits it in
a selective fashion, thus halting protein expression or viral
replication (170). Currently, in vitro vaginal tissue culture
systems have been investigated and work continues with in
vivo vaginal xenograft models to determine the optimum
dose required for maximum down-regulation of virus repli-
cation. In vitro tests utilizing fluorescent tagged siRNA in
liposomal delivery systems indicate that siRNAs are absorbed
throughout the vaginal tissue (34,171).
Lime Juice as a Microbicide
Lime juice has a long history as a contraceptive and
vaginal douche (Table V). In vitro studies of lemon/lime juice
demonstrate that it is an effective microbicide and in vivo
primate studies, repeated use of lime juice did not damage the
vagina (173). Recent studies have revealed that lime juice, at
a concentration of up 20% w/w has a good safety profile for
vaginal use. However, there is an urgent need for a systematic
study to determine if the use of lime juice can retard HIV
transmission. If it slows HIV transmission, lime juice could
prove a life saving microbicide. If the effect is modest, lime
juice might still prove to be a ‘gold standard’ microbicide with
which artificial microbicides could be compared, short
circuiting the need for time consuming expensive placebo
controlled trials (173). Thus, further research is needed to
determine the safety of lime juice at higher concentrations,
and on the effects of lime juice in women that already use it,
and on the efficacy of lime juice as an inexpensive and
ubiquitous intravaginal microbicide/spermicide used in delivery
systems.
Yoghurt as a Microbicide
Yoghurt may soon be enlisted in the battle against HIV/
AIDS (Table V). Lactobacillus, a harmless bacterium that
helps turn milk into yoghurt, has been engineered to make
HIV-fighting microbicides. Consuming yoghurt containing
Lactobacillus could provide a way for women to fend off
HIV if no other means are available (174). As well as
appearing in yoghurt, lactobacillus naturally inhabits the
human vagina. Lactobacilli play a significant physiological
role in the maintenance of the ecological balance mainly due
to lactic acid production responsible for maintaining a low pH
level in the vaginal tract. It survives the passage through the
gut and can easily traverse the short distance from the anus
and colonize the vagina. Once there, the bioengineered
bacteria could produce compounds that inhibit transmission
of HIV and maintain a normal vaginal pH, thus helping
prevent HIVand STIs infection (174–176). Administration of
preparations containing a well-characterized probiotic strains
to humans could be used to prevent or treat bacterial vaginitis
(177).
CONCLUSIONS
Intravaginal microbicide delivery systems are providing a
new option for preventing the transmission of STIs and HIV
and this could have considerable public health and economic
impact especially in resource-poor countries. As described in
this review, numerous safe and effective anti-HIV intravaginal
microbicide delivery systems are currently being evaluated at
various stages in clinical trials but to date none, which
comprise mainly gel formulations, have been found to be
fully effective at preventing the transmission of STIs and HIV.
Several clinical trials have demonstrated that intravaginal
microbicide delivery systems have the ability to protect
against the transmission of STIs and HIV but numerous
challenges still remain before these systems are used com-
mercially. It is thus anticipated that future research will focus
on the design and development of more effective intravaginal
microbicidal delivery systems for preventing the transmission
of STIs and HIV employing a wide variety of dosage forms
with multiple mechanisms of action and microbicidal delivery.
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